Glembatumumab  (Synonyms: 格巴妥木单抗)

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity^[1].

Glembatumumab vedotin (CR011-vcMMAE) (0-2.5 μg/mL，72 小时) 在未经 MEK 抑制剂预处理的 UACC62 黑色素瘤细胞中以 0.16 μg/mL 的浓度表现出极小的生长抑制，而相同剂量的 CR011-vcMMAE 表现出更强的生长对经 MEK 抑制剂预处理的 UACC62 细胞的抑制作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Glembatumumab vedotin (静脉注射，2.5 mg/kg，7 天内 3 次) 可抑制肿瘤生长，并且在 CB17SC scid^?/? 雌性肉瘤小鼠中具有良好的耐受性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1020264-78-1

液体

Colorless to light yellow

格巴妥木单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12(2):248-57.  [Content Brief]

  [2]. E Anders Kolb, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Oct;61(10):1816-21.  [Content Brief]

  [3]. Xiaozhong Qian, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol. 2008 Jun;2(1):81-93.  [Content Brief]